FDA approves BioMarin rare metabolic disorder drug, shares rise
(Reuters) – U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc’s Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending…
by October Gallery